Comparative Pharmacology
Head-to-head clinical analysis: ATENOLOL AND CHLORTHALIDONE versus CHLOROTHIAZIDE SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATENOLOL AND CHLORTHALIDONE versus CHLOROTHIAZIDE SODIUM.
ATENOLOL AND CHLORTHALIDONE vs CHLOROTHIAZIDE SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Atenolol is a cardioselective beta-1 adrenergic receptor antagonist that reduces heart rate, myocardial contractility, and blood pressure. Chlorthalidone is a thiazide-like diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and peripheral resistance.
Inhibits sodium-chloride symporter in distal convoluted tubule of nephron, reducing sodium reabsorption and promoting diuresis.
1 tablet (atenolol 50 mg/chlorthalidone 25 mg) orally once daily. May be increased to 2 tablets once daily.
500 mg to 1 g orally or intravenously once or twice daily.
None Documented
None Documented
Atenolol: 6-7 hours (prolonged to 14-27 hours in severe renal impairment); Chlorthalidone: 40-60 hours (allows once-daily dosing).
Terminal elimination half-life is 45–120 minutes in patients with normal renal function; prolonged in renal impairment (up to 24 hours in anuria).
Atenolol: ~50% eliminated unchanged in urine; Chlorthalidone: ~50-70% eliminated unchanged in urine, remainder as metabolites via renal and biliary routes (<10% fecal).
Primarily renal excretion via tubular secretion; approximately 95% of absorbed dose excreted unchanged in urine within 24 hours, with less than 5% eliminated via bile/feces.
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic